Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders

Asma Ashraf; Andreas V Hadjinicolaou; Carolyn Doree; Sally Hopewell; Marialena Trivella; Lise J Estcourt

doi:10.1002/14651858.CD012342

Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders

Cochrane Database Syst Rev. 2016 Sep 1;2016(9):CD012342. doi: 10.1002/14651858.CD012342.

Authors

Asma Ashraf¹, Andreas V Hadjinicolaou², Carolyn Doree³, Sally Hopewell⁴, Marialena Trivella⁵, Lise J Estcourt⁶

Affiliations

¹ Haematology, Calvary Mater Hospital; University of Newcastle, Waratah, Australia.
² Human Immunology Unit, Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
³ Systematic Review Initiative, NHS Blood and Transplant, Oxford, UK.
⁴ Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK.
⁵ Centre for Statistics in Medicine, University of Oxford, Oxford, UK.
⁶ Haematology/Transfusion Medicine, NHS Blood and Transplant, Oxford, UK.

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To compare a therapeutic-only versus prophylactic platelet transfusion policy for people with myelodysplasia, inherited or acquired aplastic anaemia, and other congenital bone marrow failure disorders.

Abstract

Grants and funding